Thousands of people from dozens of countries came together in Barcelona this year for Patient Community Day 2025 at the ...

The faster patients can be diagnosed with multiple sclerosis, the sooner they can begin taking the powerful medications that ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

NASCAR has settled case brought by team owners including Michael Jordan ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Mendoza has used the spotlight of being a Heisman frontrunner to highlight his mother’s fight — he calls her his “light and ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your ...